Markets:

Overview

News

Currencies

International

Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

66.88 +0.92 (+1.40%)

Streaming Delayed Price Updated: 10:55 AM EDT, May 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches ↗

Today 1:04 EDT

BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three...

Via MarketBeat

BridgeBio (BBIO) Q1 2026 Earnings Transcript ↗

May 08, 2026

BridgeBio (BBIO) Q1 2026 Earnings Transcript

Via The Motley Fool

BridgeBio Pharma (NASDAQ:BBIO) Q1 2026 Revenue Beat Driven by Attruby Sales Surge, Shares Jump ↗

May 07, 2026

Via Chartmill

BridgeBio (BBIO) Q2 2025 Earnings Transcript ↗

April 28, 2026

BridgeBio (BBIO) Q2 2025 Earnings Transcript

Via The Motley Fool

BridgeBio Pharma Inc (NASDAQ:BBIO) Posts Q4 Revenue Beat on Heart Drug Surge, Eyes Multiple 2026 NDA Submissions ↗

February 24, 2026

Via Chartmill

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity

April 13, 2026

In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL...

Via MarketMinute

Topics Economy

BridgeBio Pharma Inc (NASDAQ:BBIO) Shows High Technical and Setup Ratings Ahead of Potential Breakout ↗

April 11, 2026

BridgeBio Pharma (BBIO) shows a strong technical uptrend with a high-quality consolidation pattern, signaling a potential breakout opportunity for traders.

Via Chartmill

BridgeBio (BBIO) Q4 2025 Earnings Call Transcript ↗

February 24, 2026

BridgeBio (BBIO) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗

February 17, 2026

Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.

Via Stocktwits

Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗

February 17, 2026

Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.

Via The Motley Fool

Topics Regulatory Compliance

Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗

February 17, 2026

Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.

Via The Motley Fool

Topics Regulatory Compliance

Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗

February 17, 2026

This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates.

Via The Motley Fool

Topics Regulatory Compliance

Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance

February 12, 2026

As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as...

Via Finterra

Topics Economy Intellectual Property

BBIO Stock Surges 17% Pre-Market Today – What’s Fueling The Rally? ↗

February 12, 2026

The company reported positive results from its PROPEL 3 study of its experimental oral therapy, infigratinib, in children with achondroplasia, a genetic form of dwarfism.

Via Stocktwits

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative...

Via MarketMinute

Topics ETFs Government Initial Public Offering

BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance

January 02, 2026

In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to...

Via MarketMinute

Topics Economy Intellectual Property

The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500

January 02, 2026

As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the...

Via PredictStreet

Topics Economy Intellectual Property Stocks

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗

December 22, 2025

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

Via The Motley Fool

Topics Regulatory Compliance

How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint ↗

December 02, 2025

Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam.

Via Investor's Business Daily

BridgeBio (BBIO) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

BridgeBio (BBIO) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 14, 2025

Via Benzinga

Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds

November 10, 2025

New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings. ↗

October 30, 2025

The company easily beat third-quarter expectations and issued guidance that widely topped forecasts.

Via Investor's Business Daily

BridgeBio Pharma (NASDAQ:BBIO) Q3 2025 Revenue Beat Overshadowed by Widened Loss ↗

October 29, 2025

BridgeBio Pharma's Q3 2025 earnings show a major revenue beat driven by Attruby sales, but a widened quarterly loss led to a negative market reaction.

Via Chartmill

BridgeBio's Investigation Drug Outperforms Standard Therapy In Rare Calcium Disorder ↗

October 29, 2025

BridgeBio's Encaleret met its Phase 3 endpoint in ADH1, with 76% achieving calcium targets, supporting plans for FDA and EMA submissions in 2026.

Via Benzinga

BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results ↗

October 29, 2025

76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment.

Via Stocktwits

BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High ↗

October 29, 2025

A second positive "domino" fell for BridgeBio on Wednesday after the company reported promising results in a genetic disease.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 28, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.